Ready to Improve Your Biomarker Intelligence?

TALK TO A BIOMARKER STRATEGIST
Posts Currently viewing the category: "Uncategorized"

Recent research on clinical trial success rates that caught our eye: We are especially encouraged to see a group from MIT carrying forward the torch of drug likelihood-of-approval (LOA) analysis. That group of researchers put together this great analysis of what they call Probability of Success (POS) of clinical trials. The concept is…(Read More)

We have been working with Bio-Rad. As most of you know Bio-Rad provides the healthcare industry with innovative and useful products that help life science researchers accelerate the discovery process and medical diagnostic labs obtain faster, better results. They are one of the largest RUO and diagnostic providers in the world. Our partnership…(Read More)

We announced our new literature-focused features in our last blog post. One of the unique features of our approach is that we use deep learning concepts, a subset of machine learning, to text mine literature. A characteristic of deep learning is that various characteristics, or attributes, of a paper can be extracted. One of…(Read More)

We are excited to announce improvements to BiomarkerBase, increasing the coverage and analysis of literature. We’ve added biomarkers sourced only from literature, representing biomarkers in an earlier stage of development.  With this addition there are two main benefits: Access to biomarker and supporting information that is in an early stage of development (3x more…(Read More)

When building a company, especially a startup, you look forward to moments that change your trajectory. So, when Mary Meeker included our analysis in her annual Internet trends presentation, it got us thinking. For those of you that don’t know, Mary Meeker is a venture capitalist from the influential Silicon Valley VC, Kleiner Perkins…(Read More)

Yesterday we completed part 2 of our Safety Biomarkers and Pharmacovigilance webinar. We covered some great topics: The utility of safety biomarkers throughout the drug development process The regulatory framework for biomarker qualification Insight into how to identify biomarker information from the literature The role of biomarkers in post-marketing pharmacovigilance practices To view the…(Read More)

As we ramp for a great 2017 we are looking back on what we did in 2016. As we ramp for a great 2017 we are looking back on what we did in 2016. In that spirit, here are the top 5 blog posts of 2016 by views. FDA Introduces a New Test Concept: “Complementary…(Read More)

This week’s Chart of the Week demonstrates recent research on the correlation between the Biomarker Coverage Percent in a company’s pipeline and the Company’s Phase 3 Likelihood of Approval. This chart depicts how as a company increases their number of trials utilizing biomarkers, they will also see an increase in their likelihood…(Read More)

This week we introduced the correlation between a company’s biomarker coverage in their clinical trial pipeline and their Likelihood of Approval. After showing correlation between approval and biomarker use, we wanted to know more about a company’s biomarker use year over year. As we dove deeper into the use of biomarkers over the…(Read More)